SØG - mellem flere end 8 millioner bøger:
Viser: Pharmaceutical Economics and Policy - Perspectives, Promises, and Problems
Pharmaceutical Economics and Policy Vital Source e-bog
Stuart O. Schweitzer og Z. John Lu
(2018)
Oxford University Press
433,00 kr.
389,70 kr.
Leveres umiddelbart efter køb
Pharmaceutical Economics and Policy Vital Source e-bog
Stuart O. Schweitzer og Z. John Lu
(2018)
Oxford University Press
577,00 kr.
519,30 kr.
Leveres umiddelbart efter køb
Søgbar e-bog
Pharmaceutical Economics and Policy Vital Source e-bog
Stuart O. Schweitzer og Z. John Lu
(2018)
Oxford University Press
577,00 kr.
Leveres umiddelbart efter køb
Pharmaceutical Economics and Policy Vital Source e-bog
Stuart O. Schweitzer og Z. John Lu
(2018)
Oxford University Press
375,00 kr.
Leveres umiddelbart efter køb
Pharmaceutical Economics and Policy
Perspectives, Promises, and Problems
Stuart O. Schweitzer og Z. John Lu
(2018)
Sprog: Engelsk
Oxford University Press, Incorporated
979,00 kr.
ikke på lager, Bestil nu og få den leveret
om ca. 10 hverdage
om ca. 10 hverdage
Detaljer om varen
- 3. Udgave
- Vital Source 365 day rentals (dynamic pages)
- Udgiver: Oxford University Press (Maj 2018)
- Forfattere: Stuart O. Schweitzer og Z. John Lu
- ISBN: 9780190623807R365
Pharmaceuticals constitute a relatively small share of the total healthcare expenditure in most developed economies, and yet they play a critical role in the ongoing debate over how best to advance, improve, and afford healthcare. Despite this, and perhaps because of this, the industry has had, for many years, an outsized claim to fame and controversy, praise and criticisms, support and condemnation. Unfortunately, many participants in the debate do not fully understand the complexities of the industry and its role in the overall healthcare system. The analytical tools of economics provide a strong foundation for a better understanding of the dynamics of the pharmaceutical industry, its contribution to health and healthcare, its dual and often conflicting priorities of affordability and innovation, as well as the various private and public policy initiatives directed at the sector. This third edition of a uniquely comprehensive and balanced examination of the industry includes several new chapters on important topics such as the full-fledged generics sector, the arrival of biosimilars or generic biological drugs, the global consolidation of manufacturers, the evolving reimbursement landscape, and the emergence of the world's most populous nations, such as China, India, and Brazil, as both suppliers and consumers of pharmaceutical products. Other chapters have been fully rewritten or extensively updated, covering such important topics as the cost efficiency of research and development, pace of new innovations, economic evaluation and value-based pricing of drugs, and public and private interventions in the industry.
Licens varighed:
Bookshelf online: 365 dage fra købsdato.
Bookshelf appen: 365 dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: -1 sider kan printes ad gangen
Copy: højest -1 sider i alt kan kopieres (copy/paste)
Bookshelf online: 365 dage fra købsdato.
Bookshelf appen: 365 dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: -1 sider kan printes ad gangen
Copy: højest -1 sider i alt kan kopieres (copy/paste)
Detaljer om varen
- 3. Udgave
- Vital Source 1460 day rentals (dynamic pages)
- Udgiver: Oxford University Press (Maj 2018)
- Forfattere: Stuart O. Schweitzer og Z. John Lu
- ISBN: 9780190623807R1460
Pharmaceuticals constitute a relatively small share of the total healthcare expenditure in most developed economies, and yet they play a critical role in the ongoing debate over how best to advance, improve, and afford healthcare. Despite this, and perhaps because of this, the industry has had, for many years, an outsized claim to fame and controversy, praise and criticisms, support and condemnation. Unfortunately, many participants in the debate do not fully understand the complexities of the industry and its role in the overall healthcare system.
The analytical tools of economics provide a strong foundation for a better understanding of the dynamics of the pharmaceutical industry, its contribution to health and healthcare, its dual and often conflicting priorities of affordability and innovation, as well as the various private and public policy initiatives directed at the sector. This third edition of a uniquely comprehensive and balanced examination of the industry includes several new chapters on important topics such as the full-fledged generics sector, the arrival of biosimilars or generic biological drugs, the global consolidation of manufacturers, the evolving reimbursement landscape, and the emergence of the world's most populous nations, such as China, India, and Brazil, as both suppliers and consumers of pharmaceutical products. Other chapters have been fully rewritten or extensively updated, covering such important topics as the cost efficiency of research and development, pace of new innovations, economic evaluation and value-based pricing of drugs, and public and private interventions in the industry.
The analytical tools of economics provide a strong foundation for a better understanding of the dynamics of the pharmaceutical industry, its contribution to health and healthcare, its dual and often conflicting priorities of affordability and innovation, as well as the various private and public policy initiatives directed at the sector. This third edition of a uniquely comprehensive and balanced examination of the industry includes several new chapters on important topics such as the full-fledged generics sector, the arrival of biosimilars or generic biological drugs, the global consolidation of manufacturers, the evolving reimbursement landscape, and the emergence of the world's most populous nations, such as China, India, and Brazil, as both suppliers and consumers of pharmaceutical products. Other chapters have been fully rewritten or extensively updated, covering such important topics as the cost efficiency of research and development, pace of new innovations, economic evaluation and value-based pricing of drugs, and public and private interventions in the industry.
Licens varighed:
Bookshelf online: 1460 dage fra købsdato.
Bookshelf appen: 1460 dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: -1 sider kan printes ad gangen
Copy: højest -1 sider i alt kan kopieres (copy/paste)
Bookshelf online: 1460 dage fra købsdato.
Bookshelf appen: 1460 dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: -1 sider kan printes ad gangen
Copy: højest -1 sider i alt kan kopieres (copy/paste)
Detaljer om varen
- 3. Udgave
- Vital Source searchable e-book (Reflowable pages)
- Udgiver: Oxford University Press (Maj 2018)
- Forfattere: Stuart O. Schweitzer og Z. John Lu
- ISBN: 9780190623807
Pharmaceuticals constitute a relatively small share of the total healthcare expenditure in most developed economies, and yet they play a critical role in the ongoing debate over how best to advance, improve, and afford healthcare. Despite this, and perhaps because of this, the industry has had, for many years, an outsized claim to fame and controversy, praise and criticisms, support and condemnation. Unfortunately, many participants in the debate do not fully understand the complexities of the industry and its role in the overall healthcare system. The analytical tools of economics provide a strong foundation for a better understanding of the dynamics of the pharmaceutical industry, its contribution to health and healthcare, its dual and often conflicting priorities of affordability and innovation, as well as the various private and public policy initiatives directed at the sector. This third edition of a uniquely comprehensive and balanced examination of the industry includes several new chapters on important topics such as the full-fledged generics sector, the arrival of biosimilars or generic biological drugs, the global consolidation of manufacturers, the evolving reimbursement landscape, and the emergence of the world's most populous nations, such as China, India, and Brazil, as both suppliers and consumers of pharmaceutical products. Other chapters have been fully rewritten or extensively updated, covering such important topics as the cost efficiency of research and development, pace of new innovations, economic evaluation and value-based pricing of drugs, and public and private interventions in the industry.
Licens varighed:
Bookshelf online: 365 dage fra købsdato.
Bookshelf appen: ubegrænset dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: -1 sider kan printes ad gangen
Copy: højest -1 sider i alt kan kopieres (copy/paste)
Bookshelf online: 365 dage fra købsdato.
Bookshelf appen: ubegrænset dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: -1 sider kan printes ad gangen
Copy: højest -1 sider i alt kan kopieres (copy/paste)
Detaljer om varen
- 3. Udgave
- Vital Source 180 day rentals (dynamic pages)
- Udgiver: Oxford University Press (Maj 2018)
- Forfattere: Stuart O. Schweitzer og Z. John Lu
- ISBN: 9780190623807R180
Pharmaceuticals constitute a relatively small share of the total healthcare expenditure in most developed economies, and yet they play a critical role in the ongoing debate over how best to advance, improve, and afford healthcare. Despite this, and perhaps because of this, the industry has had, for many years, an outsized claim to fame and controversy, praise and criticisms, support and condemnation. Unfortunately, many participants in the debate do not fully understand the complexities of the industry and its role in the overall healthcare system. The analytical tools of economics provide a strong foundation for a better understanding of the dynamics of the pharmaceutical industry, its contribution to health and healthcare, its dual and often conflicting priorities of affordability and innovation, as well as the various private and public policy initiatives directed at the sector. This third edition of a uniquely comprehensive and balanced examination of the industry includes several new chapters on important topics such as the full-fledged generics sector, the arrival of biosimilars or generic biological drugs, the global consolidation of manufacturers, the evolving reimbursement landscape, and the emergence of the world's most populous nations, such as China, India, and Brazil, as both suppliers and consumers of pharmaceutical products. Other chapters have been fully rewritten or extensively updated, covering such important topics as the cost efficiency of research and development, pace of new innovations, economic evaluation and value-based pricing of drugs, and public and private interventions in the industry.
Licens varighed:
Bookshelf online: 180 dage fra købsdato.
Bookshelf appen: 180 dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: -1 sider kan printes ad gangen
Copy: højest -1 sider i alt kan kopieres (copy/paste)
Bookshelf online: 180 dage fra købsdato.
Bookshelf appen: 180 dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: -1 sider kan printes ad gangen
Copy: højest -1 sider i alt kan kopieres (copy/paste)
Detaljer om varen
- 3. Udgave
- Hardback: 432 sider
- Udgiver: Oxford University Press, Incorporated (Juni 2018)
- Forfattere: Stuart O. Schweitzer og Z. John Lu
- ISBN: 9780190623784
Pharmaceuticals constitute a relatively small share of the total healthcare expenditure in most developed economies, and yet they play a critical role in the ongoing debate over how best to advance, improve, and afford healthcare. Despite this, and perhaps because of this, the industry has had, for many years, an outsized claim to fame and controversy, praise and criticisms, support and condemnation. Unfortunately, many participants in the debate do not fully understand the complexities of the industry and its role in the overall healthcare system.
The analytical tools of economics provide a strong foundation for a better understanding of the dynamics of the pharmaceutical industry, its contribution to health and healthcare, its dual and often conflicting priorities of affordability and innovation, as well as the various private and public policy initiatives directed at the sector. This third edition of a uniquely comprehensive and balanced examination of the industry includes several new chapters on important topics such as the full-fledged generics sector, the arrival of biosimilars or generic biological drugs, the global consolidation of manufacturers, the evolving reimbursement landscape, and the emergence of the world's most populous nations, such as China, India, and Brazil, as both suppliers and consumers of pharmaceutical products. Other chapters have been fully rewritten or extensively updated, covering such important topics as the cost efficiency of research and development, pace of new innovations, economic evaluation and value-based pricing of drugs, and public and private interventions in the industry.
IntroductionThe Big PictureThe Supply of PharmaceuticalsThe Demand for PharmaceuticalsPharmaceutical PricesInternational Price ComparisonsPharmaceutical MarketingPharmaceutical PatentsRegulatory Control of the Pharmaceutical SectorTiming of Pharmaceutical ApprovalsPart I. The IndustryChapter 1 The Pharmaceutical IndustryThe Competitive Structure of the Pharmaceutical IndustryPharmaceutical Research and DevelopmentPharmaceutical R&D and PricesThe Pharmaceutical Research and Approval ProcessProduct LiabilityIncreasing Private Sector Research ActivityDrugs for Low-Income CountriesThe Role of Pharmaceutical Marketing in Prescribing DecisionsConclusionsChapter 2 The Biotechnology IndustryBackgroundWhat is Biotechnology?A Brief History of Modern Biotechnology IndustryFactors Distinguishing the Biotechnology from the Pharmaceutical IndustryCase Studies of Biotechnology Firm Growth and FailureConclusionChapter 3 Generics and BiosimilarsIntroductionA Brief History of Modern Generic Pharmaceutical Industry in the USThe Structure of the Generic Pharmaceutical IndustryGeneric Entry and Price Competition in the Pharmaceutical MarketplaceGeneric Entry and Strategic BehaviorDrug ShortageEconomic Analysis of Drug ShortageThe Emergence of BiosimilarsConclusionChapter 4 The Global Pharmaceutical IndustryGeographic Patterns of Pharmaceutical Production and SalesInternational Trade in Pharmaceutical ProductsPharmaceutical Research and Development: An International ViewDoes Government Drug Price Setting Influence R&D?Global Mergers and AcquisitionsThe Pharmaceutical Industry in Selected Countries and RegionsThe Chinese Pharmaceutical IndustryAccess to Appropriate Drugs in Developing CountriesPart II. The ConsumerChapter 5 The Demand for PharmaceuticalsThe Problem of Drug ExpendituresHow is Demand Determined?Pharmaceuticals and Other Health Services: Substitutes or Complements?The Changing Structure of the Pharmaceutical MarketConclusionChapter 6 The Demand for Pharmaceuticals in Major International MarketsComparison of Pharmaceutical Spending across Global MarketsComparison of Pharmaceutical Consumption across Global MarketsDemand for Pharmaceuticals in JapanDemand for Pharmaceuticals in ChinaDemand for Pharmaceuticals in France and GermanyDemand for Pharmaceuticals in the United KingdomDemand for Pharmaceuticals in CanadaDemand for Pharmaceuticals in BrazilConclusionPart III. Pricing and Marketing of Pharmaceutical ProductsChapter 7 Pharmaceutical PricesThe Problem of Pharmaceutical PricesPharmaceutical Prices Over TimeMeasuring Drug Prices: What Prices?Measuring Drug Prices: Rate of ChangeHow Are Drug Prices Determined?Economic Models from Industrial Organization LiteratureMarket Power, Generic Entry and PricingChapter 8 Economic Evaluation of New DrugsOptimizing Production of HealthCost-Benefit AnalysisCost-Effectiveness AnalysisCost-Utility AnalysisCost-Effectiveness League TablePolicy ApplicationsConclusionsChapter 9 Pricing Pharmaceuticals in a World EnvironmentWhy Do Drug Prices Vary Across Country?Comprehensive Comparison of International Drug PricesPolicy ImplicationsConclusionChapter 10 Pharmaceutical MarketingSize of the Pharmaceutical Promotion EffortPharmaceutical Promotion Directed at Healthcare ProvidersPharmaceutical Promotion Aimed at Patients: Direct-to-Consumer Advertising (DTCA)Pharmaceutical Promotion to Third-Party PayersRegulation of Prescription Pharmaceutical PromotionFalse and Misleading ClaimsOff-Label PromotionConclusionPart IV. Public Policies in the Pharmaceutical Market
Chapter 11 Patent Protection IntroductionPatent LawPatentabilityPatent CategoriesHow Patents Are Obtained?What Protection Does a Patent Confer?Duration of Patent ProtectionInfringement of PatentsStrategic Responses by Pharmaceutical FirmsInternational Patent TreatiesPatent Procedures under International ConventionsCriticisms of the Patent SystemPatent and Societal ChoiceChapter 12 Drug Approval Process in the United StatesThe Drug Approval Process in the United StatesThe Rising Cost of Pharmaceutical R&DMajor Drug Legislations in the United StatesAnnual NME Approvals by FDA since 2000Regulatory Approval of Generic Drugs in the USRegulatory Approval of Biosimilars in the USChapter 13 Pharmaceutical Regulation in the European UnionThe European UnionMove Toward a Single MarketHistory of Drug Regulation in EuropeStructure and Role of the European Medicines AgencyDrug Review under the European Medicines AgencyEU Rules on Labeling of Medicinal ProductsRegulations of Drug AdvertisingPharmacovigilanceApproval of Generic Drugs in the European UnionApproval of Biosimilars in the European UnionComparison of International Drug Approval LagsChapter 14 Pharmaceuticals and Public Policy: A Look AheadIndustry StructureThe Nascent Biosimilar SectorPersonalized Medicine and Digital Healthcare InformationArtificial Intelligence and MedicineOutpatient Bundled Payment Program and PharmaceuticalsPharmaceutical PricesThe FDAConclusion
Chapter 11 Patent Protection IntroductionPatent LawPatentabilityPatent CategoriesHow Patents Are Obtained?What Protection Does a Patent Confer?Duration of Patent ProtectionInfringement of PatentsStrategic Responses by Pharmaceutical FirmsInternational Patent TreatiesPatent Procedures under International ConventionsCriticisms of the Patent SystemPatent and Societal ChoiceChapter 12 Drug Approval Process in the United StatesThe Drug Approval Process in the United StatesThe Rising Cost of Pharmaceutical R&DMajor Drug Legislations in the United StatesAnnual NME Approvals by FDA since 2000Regulatory Approval of Generic Drugs in the USRegulatory Approval of Biosimilars in the USChapter 13 Pharmaceutical Regulation in the European UnionThe European UnionMove Toward a Single MarketHistory of Drug Regulation in EuropeStructure and Role of the European Medicines AgencyDrug Review under the European Medicines AgencyEU Rules on Labeling of Medicinal ProductsRegulations of Drug AdvertisingPharmacovigilanceApproval of Generic Drugs in the European UnionApproval of Biosimilars in the European UnionComparison of International Drug Approval LagsChapter 14 Pharmaceuticals and Public Policy: A Look AheadIndustry StructureThe Nascent Biosimilar SectorPersonalized Medicine and Digital Healthcare InformationArtificial Intelligence and MedicineOutpatient Bundled Payment Program and PharmaceuticalsPharmaceutical PricesThe FDAConclusion
De oplyste priser er inkl. moms
Andre har også købt:
Sickening
Af John Abramson
Af John Abramson
Pris: 235,00 kr.
Pharmaceutical and Bi...
Af Scott D. Babler ...
Af Scott D. Babler ...
Pris: 1.294,00 kr.
Atomic Habits
Af James Clear
Af James Clear
Pris: 299,00 kr.
Ten Drugs
Af Thomas Hager
Af Thomas Hager
Pris: 129,00 kr.
Ultra-Processed Peopl...
Af Chris van Tullek...
Af Chris van Tullek...
Pris: 142,00 kr.
Butikker og åbningstid
Handler du som firma
Forretningsbetingelser
Porto og forsendelse
Data & cookiepolitik
Handler du som firma
Forretningsbetingelser
Porto og forsendelse
Data & cookiepolitik
Polyteknisk Boghandel og Forlag A/S - Anker Engelundsvej 1 - 2800 Lyngby
Tlf 77 42 43 44 - email poly@polyteknisk.dk - CVR 34072655 - Sydbank Reg: 6748 Konto 0001107927
Tlf 77 42 43 44 - email poly@polyteknisk.dk - CVR 34072655 - Sydbank Reg: 6748 Konto 0001107927